These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35486722)

  • 1. High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape.
    Obermair FJ; Renoux F; Heer S; Lee CH; Cereghetti N; Loi M; Maestri G; Haldner Y; Wuigk R; Iosefson O; Patel P; Triebel K; Kopf M; Swain J; Kisielow J
    Sci Adv; 2022 Apr; 8(17):eabl5394. PubMed ID: 35486722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.
    Poluektov Y; George M; Daftarian P; Delcommenne MC
    Vaccine; 2021 Apr; 39(15):2110-2116. PubMed ID: 33744048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4
    Chen Y; Mason GH; Scourfield DO; Greenshields-Watson A; Haigh TA; Sewell AK; Long HM; Gallimore AM; Rizkallah P; MacLachlan BJ; Godkin A
    Cell Rep; 2023 Aug; 42(8):112827. PubMed ID: 37471227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.
    Liang C; Bencurova E; Psota E; Neurgaonkar P; Prelog M; Scheller C; Dandekar T
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.
    Crotzer VL; Glosson N; Zhou D; Nishino I; Blum JS
    Immunology; 2010 Nov; 131(3):318-30. PubMed ID: 20518820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loading dynamics of one SARS-CoV-2-derived peptide into MHC-II revealed by kinetic models.
    Song K; Xu H; Da LT
    Biophys J; 2023 May; 122(9):1665-1677. PubMed ID: 36964657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins.
    Zhang F; Zang TM; Stevenson EM; Lei X; Copertino DC; Mota TM; Boucau J; Garcia-Beltran WF; Jones RB; Bieniasz PD
    Proc Natl Acad Sci U S A; 2022 Oct; 119(41):e2209042119. PubMed ID: 36136978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of CD4
    Hyun YS; Lee YH; Jo HA; Baek IC; Kim SM; Sohn HJ; Kim TG
    Front Immunol; 2021; 12():774491. PubMed ID: 35069546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding profile of SARS-CoV-2 with human leukocyte antigen polymorphisms reveals critical alleles involved in immune evasion.
    Zhan Y; Ye L; Ouyang Q; Yin J; Cui J; Liu K; Guo C; Zhang H; Zhai J; Zheng C; Guo A; Sun B
    J Med Virol; 2023 Sep; 95(9):e29113. PubMed ID: 37750416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
    Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
    J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level.
    Copley HC; Gragert L; Leach AR; Kosmoliaptsis V
    Front Immunol; 2021; 12():669357. PubMed ID: 34349756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications.
    Afridi S; Hoessli DC; Hameed MW
    Immunol Rev; 2016 Jul; 272(1):151-68. PubMed ID: 27319349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
    Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
    Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression.
    Arshad N; Laurent-Rolle M; Ahmed WS; Hsu JC; Mitchell SM; Pawlak J; Sengupta D; Biswas KH; Cresswell P
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2208525120. PubMed ID: 36574644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of a Predictive Cleavage Motif for Eluted Major Histocompatibility Complex Class II Ligands.
    Paul S; Karosiene E; Dhanda SK; Jurtz V; Edwards L; Nielsen M; Sette A; Peters B
    Front Immunol; 2018; 9():1795. PubMed ID: 30127785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A virus infection-induced macroautophagy facilitates MHC class II-restricted endogenous presentation of an immunodominant viral epitope.
    Deng J; Lu C; Liu C; Oveissi S; Fairlie WD; Lee EF; Bilsel P; Puthalakath H; Chen W
    FEBS J; 2021 May; 288(10):3164-3185. PubMed ID: 33830641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus.
    Johnson DC; Hegde NR
    Curr Top Microbiol Immunol; 2002; 269():101-15. PubMed ID: 12224504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery.
    Stražar M; Park J; Abelin JG; Taylor HB; Pedersen TK; Plichta DR; Brown EM; Eraslan B; Hung YM; Ortiz K; Clauser KR; Carr SA; Xavier RJ; Graham DB
    Immunity; 2023 Jul; 56(7):1681-1698.e13. PubMed ID: 37301199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.